Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Earnings Data
Report Date
May 05, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.67Last Year’s EPS
0.42Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 06, 2025
|% Change Since: -33.49%
|Next Earnings Date:May 05, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted Neurocrine's strong performance in 2024 with record sales for INGREZZA and the successful launch of Quinicity. While there are challenges, such as increased competitive pressure and a measured launch for Quinicity, the company is taking proactive steps to address these issues. The overall sentiment is cautiously optimistic with a focus on growth and expansion in the neuroscience field.Company Guidance
During the call, Neurocrine Biosciences provided guidance for 2025, anticipating INGREZZA sales to reach between $2.5 billion and $2.6 billion, which represents an approximate $250 million growth at the midpoint compared to 2024. Although facing increased competitive pressure and utilization management by payers, the company remains focused on growing its market presence through an expanded sales force and educational efforts, aiming to address the 90% of tardive dyskinesia (TD) patients untreated with VMAT2 inhibitors. Additionally, the company expects the launch of Quinicity, targeting classical congenital adrenal hyperplasia, to have a blockbuster potential long-term, although initial revenue growth is expected to be measured due to reimbursement and patient flow dynamics. Looking ahead, Neurocrine aims to expand its clinical stage pipeline from 12 to 18 programs by year-end, with significant growth anticipated from innovative treatments in major depressive disorder and schizophrenia. The company is also aligning its 2025 SG&A and R&D expenditures to support these growth initiatives and anticipates advancing its osuvamphetor program into phase three while funding development milestones for Takeda and Nexera.Record Sales Growth for INGREZZA
2024 was a record growth year for INGREZZA, with annual sales increasing by approximately $475 million.
Quinicity Launch and FDA Approval
Quinicity received early FDA approval with a broad labeling, marking it as the first new treatment for congenital adrenal hyperplasia in over 70 years.
Expanded Neuroscience Pipeline
Neurocrine's pipeline is set to grow from 12 to 18 programs by year-end, representing one of the broadest neuroscience pipelines in the industry.
---
NBIX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NBIX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 06, 2025 | $150.51 | $122.62 | -18.53% |
| Oct 30, 2024 | $116.19 | $124.33 | +7.01% |
| Aug 01, 2024 | $141.57 | $153.15 | +8.18% |
| May 01, 2024 | $137.54 | $143.03 | +3.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neurocrine (NBIX) report earnings?
Neurocrine (NBIX) is schdueled to report earning on May 05, 2025, TBA Not Confirmed.
What is Neurocrine (NBIX) earnings time?
Neurocrine (NBIX) earnings time is at May 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NBIX EPS forecast?
NBIX EPS forecast for the fiscal quarter 2025 (Q1) is 0.67.
---